BR112017028025A2 - complexo de ferro-carboidrato para o tratamento da deficiência de ferro de um feto ou de um bebê - Google Patents

complexo de ferro-carboidrato para o tratamento da deficiência de ferro de um feto ou de um bebê

Info

Publication number
BR112017028025A2
BR112017028025A2 BR112017028025A BR112017028025A BR112017028025A2 BR 112017028025 A2 BR112017028025 A2 BR 112017028025A2 BR 112017028025 A BR112017028025 A BR 112017028025A BR 112017028025 A BR112017028025 A BR 112017028025A BR 112017028025 A2 BR112017028025 A2 BR 112017028025A2
Authority
BR
Brazil
Prior art keywords
iron
fetus
carbohydrate complex
baby
treatment
Prior art date
Application number
BR112017028025A
Other languages
English (en)
Other versions
BR112017028025B1 (pt
Inventor
Andreasen Hans
Lykke Thomsen Lars
S Christensen Tobias
Original Assignee
Pharmacosmos Holding As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacosmos Holding As filed Critical Pharmacosmos Holding As
Publication of BR112017028025A2 publication Critical patent/BR112017028025A2/pt
Publication of BR112017028025B1 publication Critical patent/BR112017028025B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

o documento revela uma composição farmacêutica compreendendo um complexo de ferro-carboidrato para uso em um método para tratamento ou prevenção da deficiência de ferro em um feto ou bebê, em que o complexo de ferro-carboidrato é administrado à mãe do feto ou bebê.
BR112017028025-6A 2015-06-22 2016-06-22 Usos de um complexo de ferro-carboidrato para o tratamento ou prevenção de uma deficiência de ferro de um feto ou de um bebê BR112017028025B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570380 2015-06-22
DKPA201570380 2015-06-22
PCT/DK2016/050216 WO2016206699A1 (en) 2015-06-22 2016-06-22 Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant

Publications (2)

Publication Number Publication Date
BR112017028025A2 true BR112017028025A2 (pt) 2018-08-28
BR112017028025B1 BR112017028025B1 (pt) 2023-04-18

Family

ID=56321686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028025-6A BR112017028025B1 (pt) 2015-06-22 2016-06-22 Usos de um complexo de ferro-carboidrato para o tratamento ou prevenção de uma deficiência de ferro de um feto ou de um bebê

Country Status (10)

Country Link
US (2) US10960081B2 (pt)
EP (2) EP3310364B1 (pt)
JP (3) JP6855392B2 (pt)
CN (4) CN116889576A (pt)
AU (1) AU2016283334B2 (pt)
BR (1) BR112017028025B1 (pt)
DK (1) DK3310364T3 (pt)
ES (1) ES2892488T3 (pt)
WO (1) WO2016206699A1 (pt)
ZA (1) ZA201707463B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111050802A (zh) 2017-09-11 2020-04-21 法码科思莫斯控股有限公司 用于治疗用途的铁络合物化合物
WO2023012242A1 (en) * 2021-08-03 2023-02-09 Pharmacosmos Holding A/S Iron complex compounds for subcutaneous use in therapy of iron deficiency in companion animals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080009075A (ko) * 2005-03-10 2008-01-24 씰 파마, 인크. 영양 제제
AU2007205167B2 (en) 2006-01-06 2013-06-13 Vifor (International) Ag Methods and compositions for administration of iron
US8071542B2 (en) 2007-01-29 2011-12-06 Chyna, LLC Use of ferritin to treat iron deficiency disorders
AU2008353469B2 (en) 2008-03-28 2014-12-11 Chyna Llc Use of ferritin to treat iron deficiency disorders
BRPI0924653B8 (pt) * 2009-03-25 2021-05-25 Pharmacosmos Holding As composto de ferro-oligossacarídeo, composição e uso de deste composto
EP2913054A1 (en) 2015-03-19 2015-09-02 Pharmacosmos Holding A/s Iron carbohydrate complex for treatment of restless leg syndrome (rls)

Also Published As

Publication number Publication date
JP2022169561A (ja) 2022-11-09
JP2018518497A (ja) 2018-07-12
EP3310364B1 (en) 2021-09-15
US20180133335A1 (en) 2018-05-17
AU2016283334A1 (en) 2017-11-23
US10960081B2 (en) 2021-03-30
US20210268118A1 (en) 2021-09-02
DK3310364T3 (da) 2021-10-11
JP6855392B2 (ja) 2021-04-07
AU2016283334B2 (en) 2021-03-11
WO2016206699A1 (en) 2016-12-29
JP2021011487A (ja) 2021-02-04
CN116898874A (zh) 2023-10-20
EP3310364A1 (en) 2018-04-25
EP3988103A1 (en) 2022-04-27
ES2892488T3 (es) 2022-02-04
CN116999459A (zh) 2023-11-07
CN116889576A (zh) 2023-10-17
CN107820428A (zh) 2018-03-20
ZA201707463B (en) 2018-11-28
JP7158444B2 (ja) 2022-10-21
BR112017028025B1 (pt) 2023-04-18
US11633489B2 (en) 2023-04-25

Similar Documents

Publication Publication Date Title
CY1123845T1 (el) Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112016017317A8 (pt) composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1
BR112017010440A2 (pt) administração sublingual de riluzol
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112017010423A2 (pt) formulação sublingual de riluzol
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112018013833A2 (pt) métodos de administração de hepcidina
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
BR112017024163A2 (pt) compostos bicíclicos
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PH12017500923A1 (en) New dosage and use of a a2a antagonist
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
BR112017028025A2 (pt) complexo de ferro-carboidrato para o tratamento da deficiência de ferro de um feto ou de um bebê
BR112019004540A2 (pt) método para tratar demência em um paciente, composição farmacêutica, método para tratar demência em um paciente, método para reduzir a probabilidade de desenvolver demência em um paciente, composição para uso no tratamento de demência em um paciente, composição e composição para uso na redução da probabilidade de desenvolver demência em um paciente submetido a uma terapia longa de um fármaco não-esteroide anti-inflamatório ou aspirina
MX2016000037A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
BR112017009193A2 (pt) método de tratamento de uma doença infecciosa, câncer, ou doença mieloproliferativa em um indivíduo; método de tratamento de uma doença mieloproliferativa em um indivíduo; e; interferon tipo i
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/06/2016, OBSERVADAS AS CONDICOES LEGAIS